← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

NTRA logoNatera, Inc.(NTRA)Earnings, Financials & Key Ratios

NTRA•NASDAQ
$219.82
$31.16B mkt cap·Price updated May 7, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryMolecular and Genetic Diagnostics
AboutNatera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.Show more
  • Revenue$2.31B+35.9%
  • EBITDA-$264M-38.0%
  • Net Income-$208M-9.3%
  • EPS (Diluted)-1.52+0.7%
  • Gross Margin64.85%+7.6%
  • EBITDA Margin-11.45%-1.5%
  • Operating Margin-13.44%-2.6%
  • Net Margin-9.03%+19.6%
  • ROE-14.32%+26.3%
  • ROIC-36.1%-8.5%
  • Debt/Equity0.13-20.0%
  • Interest Coverage-64.89-287.2%
Analysis→Technical→

NTRA Key Insights

Natera, Inc. (NTRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Strong 5Y sales CAGR of 42.6%

✗Weaknesses

  • ✗Expensive at 17.6x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

NTRA Price & Volume

Natera, Inc. (NTRA) stock price & volume — 10-year historical chart

Loading chart...

NTRA Growth Metrics

Natera, Inc. (NTRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years28.33%
5 Years42.61%
3 Years41.14%
TTM35.9%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-9.31%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM0%

Return on Capital

10 Years-53.32%
5 Years-36.33%
3 Years-25.56%
Last Year-18.32%

NTRA Recent Earnings

Natera, Inc. (NTRA) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 12/12 qtrs (100%)
Q1 2026Latest
Feb 26, 2026
EPS
$0.35
Est $0.51
+168.3%
Revenue
$666M
Est $604M
+10.2%
Q4 2025
Nov 6, 2025
EPS
$0.64
Est $0.39
-65.9%
Revenue
$592M
Est $513M
+15.3%
Q3 2025
Aug 7, 2025
EPS
$0.74
Est $0.62
-20.2%
Revenue
$547M
Est $476M
+14.8%
Q2 2025
May 8, 2025
EPS
$0.50
Est $0.64
+21.9%
Revenue
$502M
Est $446M
+12.5%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q1 2026LatestFeb 26, 2026
$0.35vs $0.51+168.3%
$666Mvs $604M+10.2%
Q4 2025Nov 6, 2025
$0.64vs $0.39-65.9%
$592Mvs $513M+15.3%
Q3 2025Aug 7, 2025
$0.74vs $0.62-20.2%
$547Mvs $476M+14.8%
Q2 2025May 8, 2025
$0.50vs $0.64+21.9%
$502Mvs $446M+12.5%
Based on last 12 quarters of dataView full earnings history →

NTRA Peer Comparison

Natera, Inc. (NTRA) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
EXAS logoEXASExact Sciences CorporationDirect Competitor20.02B104.91-95.3717.69%-6.4%-8.66%1.05
ILMN logoILMNIllumina, Inc.Direct Competitor21.07B138.7125.45-0.78%19.43%32.84%0.94
CGEN logoCGENCompugen Ltd.Direct Competitor256.09M2.86-17.88-16.72%-5.77%-71.54%0.05
MYRG logoMYRGMYR Group Inc.Product Competitor6.65B427.3856.768.79%3.71%22.14%0.16
PACB logoPACBPacific Biosciences of California, Inc.Product Competitor498.3M1.65-0.913.89%-341.47%-11.23%141.98
PRME logoPRMEPrime Medicine, Inc.Product Competitor562.42M3.12-2.3155.28%-62.42%-188.82%0.96
CDNA logoCDNACareDx, IncProduct Competitor1.11B21.44-53.6013.79%-1.98%-2.61%0.06
TMO logoTMOThermo Fisher Scientific Inc.Supply Chain176.36B474.5626.753.91%15.18%13.23%0.76

Compare NTRA vs Peers

Natera, Inc. (NTRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs EXAS

Most directly comparable listed peer for NTRA.

Scale Benchmark

vs TMO

Larger-name benchmark to compare NTRA against a more recognizable public peer.

Peer Set

Compare Top 5

vs EXAS, ILMN, CGEN, MYRG

NTRA Income Statement

Natera, Inc. (NTRA) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue210.94M257.65M302.33M391M625.49M820.22M1.08B1.7B2.31B
Revenue Growth %-2.83%22.15%17.34%29.33%59.97%31.13%31.99%56.75%35.9%
Cost of Goods Sold139.6M166.06M175.47M203.62M318.42M456.26M589.83M673.75M810.63M
COGS % of Revenue66.18%64.45%58.04%52.08%50.91%55.63%54.48%39.7%35.15%
Gross Profit
71.34M▲ 0%
91.6M▲ 28.4%
126.86M▲ 38.5%
187.38M▲ 47.7%
307.07M▲ 63.9%
363.97M▲ 18.5%
492.74M▲ 35.4%
1.02B▲ 107.6%
1.5B▲ 46.2%
Gross Margin %33.82%35.55%41.96%47.92%49.09%44.37%45.52%60.3%64.85%
Gross Profit Growth %-12.46%28.39%38.49%47.71%63.87%18.53%35.38%107.65%46.16%
Operating Expenses205.37M206.23M243.15M403.66M775.24M905.01M938.99M1.25B1.81B
OpEx % of Revenue97.36%80.04%80.42%103.24%123.94%110.34%86.74%73.4%78.29%
Selling, General & Admin155.31M154.87M206.18M303.63M511.03M588.59M618.31M841.31M1.18B
SG&A % of Revenue73.63%60.11%68.2%77.65%81.7%71.76%57.11%49.58%51.05%
Research & Development50.06M51.35M51.36M100.03M264.21M316.42M320.68M404.14M624.11M
R&D % of Revenue23.73%19.93%16.99%25.58%42.24%38.58%29.62%23.82%27.06%
Other Operating Expenses00-14.39M000004.03M
Operating Income
-134.03M▲ 0%
-114.63M▲ 14.5%
-116.29M▼ 1.4%
-216.28M▼ 86.0%
-468.17M▼ 116.5%
-541.04M▼ 15.6%
-446.25M▲ 17.5%
-222.29M▲ 50.2%
-309.91M▼ 39.4%
Operating Margin %-63.54%-44.49%-38.46%-55.31%-74.85%-65.96%-41.22%-13.1%-13.44%
Operating Income Growth %-38.91%14.47%-1.45%-85.99%-116.47%-15.56%17.52%50.19%-39.41%
EBITDA-126.88M-107.13M-108.56M-207.66M-456.92M-510.57M-407.63M-191.33M-264.02M
EBITDA Margin %-60.15%-41.58%-35.91%-53.11%-73.05%-62.25%-37.65%-11.28%-11.45%
EBITDA Growth %-40.5%15.57%-1.33%-91.29%-120.03%-11.74%20.16%53.06%-37.99%
D&A (Non-Cash Add-back)7.14M7.5M7.73M8.61M11.25M30.47M38.62M30.97M0
EBIT-132.96M-114.63M-112.14M-214.56M-462.79M-537.5M-421.89M-179.05M-264.02M
Net Interest Income-1.83M-13.21M-6.54M-7.52M-2.92M-5.78M11.71M32.56M-4.07M
Interest Income2.38M04.15M7.56M5.38M3.54M24.35M43.25M0
Interest Expense4.21M10.48M10.69M15.08M8.3M9.32M12.64M10.69M4.07M
Other Income/Expense-1.83M-13.21M-6.54M-13.37M-2.92M-5.78M11.71M32.56M41.82M
Pretax Income
-135.86M▲ 0%
-127.83M▲ 5.9%
-122.83M▲ 3.9%
-229.65M▼ 87.0%
-471.1M▼ 105.1%
-546.82M▼ 16.1%
-434.53M▲ 20.5%
-189.73M▲ 56.3%
-268.09M▼ 41.3%
Pretax Margin %-64.41%-49.61%-40.63%-58.73%-75.32%-66.67%-40.14%-11.18%-11.63%
Income Tax454K321K2M98K618K978K271K695K-59.93M
Effective Tax Rate %-0.33%-0.25%-1.63%-0.04%-0.13%-0.18%-0.06%-0.37%22.35%
Net Income
-136.31M▲ 0%
-128.15M▲ 6.0%
-124.83M▲ 2.6%
-229.74M▼ 84.0%
-471.72M▼ 105.3%
-547.8M▼ 16.1%
-434.8M▲ 20.6%
-190.43M▲ 56.2%
-208.16M▼ 9.3%
Net Margin %-64.62%-49.74%-41.29%-58.76%-75.42%-66.79%-40.16%-11.22%-9.03%
Net Income Growth %-42.34%5.99%2.6%-84.05%-105.32%-16.13%20.63%56.2%-9.31%
Net Income (Continuing)-137.63M-128.15M-124.83M-229.74M-471.72M-547.8M-434.8M-190.43M-208.16M
Discontinued Operations000000000
Minority Interest000000000
EPS (Diluted)
-2.54▲ 0%
-2.22▲ 12.6%
-1.79▲ 19.4%
-2.84▼ 58.7%
-5.21▼ 83.5%
-5.57▼ 6.9%
-3.78▲ 32.1%
-1.53▲ 59.5%
-1.52▲ 0.7%
EPS Growth %-36.56%12.6%19.37%-58.66%-83.45%-6.91%32.14%59.52%0.65%
EPS (Basic)-2.56-2.22-1.79-2.84-5.21-5.57-3.78-1.53-1.52
Diluted Shares Outstanding53.6M57.85M69.56M81.01M90.56M98.41M115M124.72M136.72M
Basic Shares Outstanding53.31M57.73M69.56M81.01M90.56M98.41M115M124.72M136.72M
Dividend Payout Ratio---------

NTRA Balance Sheet

Natera, Inc. (NTRA) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets180.63M240.52M523.17M862.66M1.09B1.21B1.26B1.38B1.5B
Cash & Short-Term Investments118.87M153.87M440.99M737.27M914.28M898.39M878.98M968.28M1.08B
Cash Only12.62M46.41M61.93M48.67M84.39M466.09M642.1M945.59M1.08B
Short-Term Investments106.25M107.46M379.06M688.61M829.9M432.3M236.88M22.69M0
Accounts Receivable44.09M62.22M53.35M78.56M122.07M244.38M278.29M314.17M296.53M
Days Sales Outstanding76.2988.1564.4173.3471.24108.7593.8367.5846.93
Inventory9M13.63M12.39M20.03M26.91M35.41M40.76M44.74M68.44M
Days Inventory Outstanding23.5329.9725.7835.9130.8528.3225.2224.2430.82
Other Current Assets59K4.6M55K187K228K33.63M60.52M48.63M55.83M
Total Non-Current Assets33.99M27.65M59.49M69.49M143.35M182.66M183.15M284.92M1.01B
Property, Plant & Equipment29.67M24.34M47.01M54.75M124.53M164.33M167.75M248.19M349.73M
Fixed Asset Turnover7.11x10.59x6.43x7.14x5.02x4.99x6.45x6.84x6.59x
Goodwill00000000141.07M
Intangible Assets00000000373.71M
Long-Term Investments000000000
Other Non-Current Assets4.32M3.32M12.48M14.74M18.82M18.33M15.4M36.72M36.9M
Total Assets
214.61M▲ 0%
268.17M▲ 25.0%
582.66M▲ 117.3%
932.15M▲ 60.0%
1.24B▲ 32.6%
1.39B▲ 12.8%
1.44B▲ 3.4%
1.66B▲ 15.2%
2.51B▲ 51.0%
Asset Turnover0.98x0.96x0.52x0.42x0.51x0.59x0.75x1.02x0.92x
Asset Growth %1.87%24.96%117.27%59.98%32.65%12.78%3.39%15.19%51.02%
Total Current Liabilities105.56M113.98M179.87M199.05M218.96M310.5M307.27M344.05M441.23M
Accounts Payable8.53M14.59M8.6M8.1M27.21M31.15M15M34.92M33.16M
Days Payables Outstanding22.332.0617.914.5131.1924.929.2818.9214.93
Short-Term Debt50.11M50.15M50.12M50.05M50.05M80.35M80.4M80.36M95.9M
Deferred Revenue (Current)1.42M4.13M56.02M50.13M7.4M10.78M16.61M19.75M24.91M
Other Current Liabilities19.04M22.68M25.5M47.74M58.15M62.96M69.1M73.39M186.29M
Current Ratio1.71x2.11x2.91x4.33x4.99x3.90x4.10x4.00x3.39x
Quick Ratio1.63x1.99x2.84x4.23x4.87x3.79x3.96x3.87x3.24x
Cash Conversion Cycle77.5286.0572.2994.7370.9112.16109.7772.962.82
Total Non-Current Liabilities83.64M122.03M124.07M246.86M364.23M378.23M369.1M121.27M354.4M
Long-Term Debt73.06M73.36M73.66M202.49M280.39M281.65M282.94M00
Capital Lease Obligations0026.3M21.25M61.04M76.58M67.03M96.59M118.47M
Deferred Tax Liabilities00000000110.39M
Other Non-Current Liabilities10.57M8.61M310K320K1.48M000108.47M
Total Liabilities189.2M236.01M303.94M445.92M583.18M688.73M676.37M465.31M795.62M
Total Debt123.18M123.51M155.81M281.09M397.23M446.22M441.99M187.12M214.38M
Net Debt110.56M77.1M93.89M232.43M312.85M-19.87M-200.1M-758.47M-861.76M
Debt / Equity4.85x3.84x0.56x0.58x0.61x0.63x0.58x0.16x0.13x
Debt / EBITDA---------
Net Debt / EBITDA---------
Interest Coverage-31.56x-10.94x-10.49x-14.23x-55.72x-57.68x-33.38x-16.76x-64.89x
Total Equity
25.42M▲ 0%
32.16M▲ 26.5%
278.71M▲ 766.6%
486.24M▲ 74.5%
653.3M▲ 34.4%
705.74M▲ 8.0%
765.33M▲ 8.4%
1.2B▲ 56.2%
1.71B▲ 43.2%
Equity Growth %-76.13%26.54%766.58%74.46%34.36%8.03%8.44%56.2%43.25%
Book Value per Share0.470.564.016.007.217.176.669.5812.52
Total Shareholders' Equity25.42M32.16M278.71M486.24M653.3M705.74M765.33M1.2B1.71B
Common Stock6K7K8K9K10K11K11K12K14K
Retained Earnings-446.38M-574.53M-699.17M-929.32M-1.39B-1.94B-2.38B-2.57B-2.78B
Treasury Stock000000000
Accumulated OCI-766K-552K919K4.26M-2.29M-16.36M-3.08M-344K-258K
Minority Interest000000000

NTRA Cash Flow Statement

Natera, Inc. (NTRA) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-97.83M-70.58M-63.44M-182.51M-335.24M-431.5M-246.96M135.66M215.3M
Operating CF Margin %-46.38%-27.39%-20.99%-46.68%-53.6%-52.61%-22.81%7.99%9.34%
Operating CF Growth %-32.1%27.85%10.11%-187.67%-83.68%-28.72%42.77%154.93%58.7%
Net Income-137.63M-128.15M-124.83M-229.74M-471.72M-547.8M-434.8M-190.43M-208.16M
Depreciation & Amortization7.14M7.5M7.73M8.61M11.25M16.7M24.1M30.97M0
Stock-Based Compensation11.4M14.2M28.62M50.17M115.22M152.38M191.81M274.43M0
Deferred Taxes000000000
Other Non-Cash Items1.65M8.72M-2.17M27.58M55.61M30.36M19.89M18.55M352.62M
Working Capital Changes19.61M27.16M27.2M-39.13M-45.6M-83.15M-47.95M2.14M70.84M
Change in Receivables6.32M-18.09M2.42M-25.83M-43.51M-122.31M-33.9M-35.88M20.75M
Change in Inventory-3.09M-4.9M917K-7.47M-6.88M-8.5M-5.35M-3.98M-20.87M
Change in Payables217K3.78M-6.26M-118K19.22M5.46M-15.46M13.21M753K
Cash from Investing13.78M-5.16M-266.35M-331.46M-205.19M330.34M168.5M137.62M-132.21M
Capital Expenditures-9.87M-3.88M-4.97M-19.6M-41.03M-47.7M-39.2M-66.42M-139.19M
CapEx % of Revenue4.68%1.51%1.64%5.01%6.56%5.82%3.62%3.91%6.04%
Acquisitions009.68M00000-16.02M
Investments---------
Other Investing0000-8.56M00-10.49M0
Cash from Financing80.37M113.72M340.77M500.85M576.19M482.64M254.46M30.2M47.46M
Debt Issued (Net)75M00199.56M030M0-82K0
Equity Issued (Net)5.66M113.72M340.77M301.29M576.19M452.64M254.46M30.29M47.46M
Dividends Paid000000000
Share Repurchases000000000
Other Financing-287K00000000
Net Change in Cash
-3.67M▲ 0%
37.98M▲ 1135.2%
10.98M▼ 71.1%
-13.13M▼ 219.6%
35.76M▲ 372.4%
381.48M▲ 966.8%
176M▼ 53.9%
303.49M▲ 72.4%
130.55M▼ 57.0%
Free Cash Flow
-106.66M▲ 0%
-74.46M▲ 30.2%
-68.41M▲ 8.1%
-202.12M▼ 195.4%
-376.27M▼ 86.2%
-479.2M▼ 27.4%
-286.15M▲ 40.3%
69.24M▲ 124.2%
109.11M▲ 57.6%
FCF Margin %-50.56%-28.9%-22.63%-51.69%-60.16%-58.42%-26.43%4.08%4.73%
FCF Growth %-9.91%30.19%8.12%-195.44%-86.16%-27.36%40.28%124.2%57.58%
FCF per Share-1.99-1.29-0.98-2.49-4.15-4.87-2.490.560.80
FCF Conversion (FCF/Net Income)0.72x0.55x0.51x0.79x0.71x0.79x0.57x-0.71x-1.03x
Interest Paid3.57M7.91M12.46M3.3M7.08M8.06M11.35M7.9M0
Taxes Paid177K332K2.15M67K283K549K295K1.31M0

NTRA Key Ratios

Natera, Inc. (NTRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2016201720182019202020212022202320242025
Return on Equity (ROE)-65.76%-206.7%-445.14%-80.31%-60.07%-82.79%-80.62%-59.11%-19.42%-14.32%
Return on Invested Capital (ROIC)-42.73%-72.63%-70.11%-36.2%-29.73%-41.68%-49.13%-53.5%-33.27%-36.1%
Gross Margin37.54%33.82%35.55%41.96%47.92%49.09%44.37%45.52%60.3%64.85%
Net Margin-44.12%-64.62%-49.74%-41.29%-58.76%-75.42%-66.79%-40.16%-11.22%-9.03%
Debt / Equity0.47x4.85x3.84x0.56x0.58x0.61x0.63x0.58x0.16x0.13x
Interest Coverage-186.96x-31.56x-10.94x-10.49x-14.23x-55.72x-57.68x-33.38x-16.76x-64.89x
FCF Conversion0.77x0.72x0.55x0.51x0.79x0.71x0.79x0.57x-0.71x-1.03x
Revenue Growth14.04%-2.83%22.15%17.34%29.33%59.97%31.13%31.99%56.75%35.9%

NTRA SEC Filings & Documents

Natera, Inc. (NTRA) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 7, 2026·SEC

Material company update

Apr 1, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

1
FY 2026

Feb 27, 2026·SEC

10-Q Quarterly Reports

3
FY 2025

Nov 7, 2025·SEC

FY 2025

Aug 8, 2025·SEC

FY 2025

May 9, 2025·SEC

NTRA Frequently Asked Questions

Natera, Inc. (NTRA) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Natera, Inc. (NTRA) reported $2.31B in revenue for fiscal year 2025. This represents a 16083% increase from $14.3M in 2012.

Natera, Inc. (NTRA) grew revenue by 35.9% over the past year. This is strong growth.

Natera, Inc. (NTRA) reported a net loss of $208.2M for fiscal year 2025.

Dividend & Returns

Natera, Inc. (NTRA) has a return on equity (ROE) of -14.3%. Negative ROE indicates the company is unprofitable.

Natera, Inc. (NTRA) generated $96.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

Explore More NTRA

Natera, Inc. (NTRA) financial analysis — history, returns, DCA and operating performance tools

Full NTRA Stock Analysis

Analyst verdict, bull/bear case, risk factors and peer comparison

→

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.